Author | Christopher R. Flowers, MD, MS


Strategies for Overcoming Disparities for Patients With Hematologic Malignancies and for Improving Enrollment on Clinical Trials

June 16, 2020

A multitude of factors contributes to cancer disparities. Addressing these disparities among racial/ethnic minority populations with blood cancers requires multilevel models of the interactions between relevant factors and the performance of translational research that uses knowledge of cancer biology to develop and test the feasibility of interventions that can impact human endpoints. To be effective, efforts should be made to advance these research findings to applications that can transform clinical practice and health care delivery. We reviewed the literature to define a framework for overcoming disparities for patients with hematologic malignancies and to improve patient enrollment in clinical trials.

How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis

June 15, 2018

Here we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.

ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma

December 15, 2016

By combining the most recent medical literature and expert opinion, this revised guideline can aid clinicians in the complex decision-making associated with the management of recurrent Hodgkin lymphoma.

A Plethora of Novel Therapies-Which One to Choose?

July 15, 2015

While the headliners for the 2015 ASCO Annual Meeting featured mainly immunologic approaches to cancer treatment, with agents such as nivolumab and ipilimumab, the new data in hematologic malignancies highlighted a large number of novel therapies, each of which appears promising.